

**Amendments To The Claims**

1-22. (Canceled)

23. (Currently amended) A method of treating B cell lymphoma comprising administering a therapeutically effective amount of an anti-B7.1 antibody, The method of claim 21 wherein said antibody binds the same epitope as an anti-B7.1 antibody selected from the group consisting of 7C10, which has the variable sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOS 1-2 and 3-4 respectively); 7B6, which has the variable sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOS. 5-6 and 7-8 respectively); and 16C10, which has the variable sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOS. 9-10 and 11-12 respectively).

24. (Previously presented) The method of claim 23 wherein said anti-B7 antibody binds the same epitope as an anti-B7.1 antibody selected from the group consisting of 16C10, 7C10, 20C9 and 7B6.

25. (Canceled)

26. (Currently amended) The method of claim 21 23 wherein said antibody is a non-depleting antibody.

27-31. (Canceled)

32. (Currently amended) The method of claim 21 23 wherein the antibody is a primatized antibody having the variable sequences of an anti-B7.1 antibody selected from the group consisting of 7C10, which has the variable sequences shown in Figures 8a and 8b (amino acid sequences of SEQ ID NOS. 1-2 and 3-4, respectively); 7B6, which has the variable sequences shown in Figures 9a and 9b (amino acid sequences of SEQ ID NOS. 5-6 and 7-8, respectively); and 16C10, which has the variable sequences shown in Figures 10a and 10b (amino acid sequences of SEQ ID NOS. 9-10 and 11-12 respectively).

33-36. (Canceled)

37. (Original) The method of claim 32 where the antibody is a primatized antibody having the variable sequences of antibody 16C10 shown in figures 10a and 10b (amino acid

sequences of SEQ ID NOS. 9-10 and 11-12, respectively).